Home » Newsletters » BioWorld Science

BioWorld Science

July 29, 2021

View Archived Issues

Chengdu Baiyu Pharmaceutical presents new tetrahydrocannabinol derivatives

New RORgammaT agonists identified at Sunshine Lake Pharma

Jiangsu Hansoh Pharmaceutical, Shanghai Hansoh Biomedical patent PD-1/PD-L1 inhibitors

First patients dosed in new studies of Xpovio in melanoma and myelofibrosis

FDA authorizes phase II study of autologous adipose-derived mesenchymal stem cells in MS

Vonafexor meets primary endpoint in the phase IIa LIVIFY study in patients with NASH

New serine-protein kinase ATM inhibitors described by Medshine Discovery

ISIS-814907 well tolerated in first-in-human study in mild Alzheimer's disease patients

MMV-688533 shows excellent single-dose efficacy in P. falciparum-infected mouse model

Selinexor shows antiviral and the anti-inflammatory effects in models of SARS-CoV-2 infection

Phase II study of CETP inhibitor obicetrapib meets primary endpoint

IDMC of phase II study of EscharEx for venous leg ulcers recommends continuation of trial

Targeting the IL-8/CXCR2 axis as a potential therapeutic strategy in prostate cancer

New phase Ib/II trial evaluates pembrolizumab combination therapies in second-line ES-SCLC

Venatorx reports phase I data on beta-lactamase inhibitor VNRX-7145

Arcturus cleared to begin phase II study of ARCT-810 for OTC deficiency

Clarity initiates phase I/IIa theranostic trial of 64/67Cu SAR-bisPSMA in metastatic CRPC

Restoring chondroitin 6-sulfate can rescue age-related memory impairment

Daewoong reports phase IIb topline data on Foistar in mild COVID-19

FDA clears INDs for targeted alpha therapy FPI-1966 and imaging agent FPI-1967

Blueprint Medicines and MD Anderson collaborate on advancing CDK2 inhibitor BLU-222

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...